Nathanael G Bailey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5624946/publications.pdf

Version: 2024-02-01

42 papers	1,367 citations	471509 17 h-index	395702 33 g-index
42 all docs	42 docs citations	42 times ranked	2560 citing authors

#	Article	IF	Citations
1	Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. Journal of Experimental Medicine, 2012, 209, 1553-1565.	8.5	274
2	Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood, 2014, 124, 1460-1472.	1.4	202
3	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAKâ€“STAT pathway in SÃ©zary syndrome. Nature Communications, 2015, 6, 8470.	12.8	177
4	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood, 2014, 123, 3007-3015.	1.4	158
5	A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood, 2014, 124, 3768-3771.	1.4	90
6	T-cell Receptor Signaling Activates an ITK/NF-ÎºB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. Clinical Cancer Research, 2017, 23, 2506-2515.	7.0	49
7	Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2â€“MALT1 in MALT lymphoma. Nature Communications, 2015, 6, 5908.	12.8	44
8	Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 6118-6128.	7.0	42
9	Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability. Clinical Cancer Research, 2020, 26, 690-703.	7.0	41
10	Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy. Archives of Pathology and Laboratory Medicine, 2015, 139, 1215-1223.	2.5	34
11	Disease Progression in a Patient With Indolent T-Cell Lymphoproliferative Disease of the Gastrointestinal Tract. International Journal of Surgical Pathology, 2019, 27, 102-107.	0.8	34
12	Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6581-6586.	7.1	32
13	Evaluation of Allele-Specific PCR and Immunohistochemistry for the Detection of BRAF V600E Mutations in Hairy Cell Leukemia. American Journal of Clinical Pathology, 2015, 143, 89-99.	0.7	28
14	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. Human Pathology, 2020, 106, 93-105.	2.0	27
15	A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral Tâ€cell lymphomas. American Journal of Hematology, 2017, 92, 1287-1294.	4.1	21
16	Diagnosis of Splenic B-Cell Lymphomas in the Bone Marrow: A Review of Histopathologic, Immunophenotypic, and Genetic Findings. Archives of Pathology and Laboratory Medicine, 2014, 138, 1295-1301.	2.5	19
17	Survival following salvage therapy for primary refractory peripheral Tâ€cell lymphomas (PTCL). American Journal of Hematology, 2018, 93, 394-400.	4.1	19
18	Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget, 2017, 8, 114474-114480.	1.8	15

#	Article	IF	Citations
19	Aggressive Myeloid Sarcoma Causing Recurrent Spinal Cord Compression. World Neurosurgery, 2015, 84, 866.e7-866.e10.	1.3	10
20	North American Blastomycosis of the Eyelid. Ophthalmic Plastic and Reconstructive Surgery, 2009, 25, 230-232.	0.8	6
21	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. American Journal of Clinical Pathology, 2019, 152, 277-301.	0.7	6
22	BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma. Cancer Research Communications, 2022, 2, 220-232.	1.7	6
23	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. Surgical Pathology Clinics, 2016, 9, 41-54.	1.7	5
24	Metastatic alveolar rhabdomyosarcoma to the bone marrow mimicking acute leukemia. Blood, 2012, 120, 3632-3632.	1.4	4
25	Aggressive genetic â€œdouble-hitâ€•B-cell lymphoma following renal transplantation: case report. Journal of Hematopathology, 2013, 6, 39-43.	0.4	4
26	Molecular Diagnostics of T-Cell Lymphoproliferative Disorders. Cancer Journal (Sudbury, Mass), 2014, 20, 48-60.	2.0	4
27	Mature T-cell leukemias: Molecular and Clinical Aspects. Current Hematologic Malignancy Reports, 2015, 10, 421-428.	2.3	4
28	Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. Journal of Clinical Pathology, 2020, 73, 728-736.	2.0	4
29	In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported. Blood Advances, 2021, 5, 5057-5059.	5.2	2
30	Imatinib Treatment in PDGFRAâ€Negative Childhood Hypereosinophilic Syndrome. Pediatric Blood and Cancer, 2016, 63, 164-167.	1.5	1
31	What is new in mature T-cell leukemias?. Seminars in Diagnostic Pathology, 2020, 37, 72-78.	1.5	1
32	One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia. Archives of Pathology and Laboratory Medicine, 2021, , .	2.5	1
33	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035444.	6.2	1
34	Molecular Testing in Hematologic Malignancies. , 2014, , 135-167.		1
35	NPM-ALK Mediated Tyrosine Phosphorylation of ATP Citrate Lyase Regulates Lipid Metabolism and Promotes Oncogenesis of Anaplastic Large Cell Lymphoma. Blood, 2015, 126, 465-465.	1.4	1
36	Genomic Basis of Pediatric Lymphomas. , 2014, , 341-355.		0

#	Article	IF	Citations
37	Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?. Journal of Hematopathology, 2021, 14, 3-14.	0.4	0
38	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	1.4	0
39	N-Glycoproteomic Landscape of Human Lymphoid Cancers Reveals Novel Biomarkers and Potential Therapeutic Targets. Blood, 2015, 126, 697-697.	1.4	0
40	Hyperactive Nras and Dose Reduction of Tet2 Collaborate to Dys-Regulate Hematopoietic Stem Cells and Promote Leukemogenesis. Blood, 2016, 128, 1204-1204.	1.4	0
41	Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 2016, 128, 4152-4152.	1.4	0
42	Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement. Genes, 2022, 13, 432.	2.4	0